Drug profile · INN
chlorotrianisene
TACE
chlorotrianisene (TACE) is a estrogen receptor beta modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — chlorotrianisene
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 7
- Programs
- 7
- Data quality
- 0.84
Quick answer
chlorotrianisene (TACE) is a estrogen receptor beta modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Estrogen receptor beta modulator
Primary target: Estrogen receptor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 9346866
Inhibition of tace activity with cyclic peptides
granted -
US 8168588
Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions
granted -
US 7919520
Inhibitors of tace
granted -
US 7485664
Inhibitors of TACE
granted -
US 6825165
Betacellulin modification
expired -
US 6183971
Human betacellulin-specific antibodies and uses thereof
expired -
US 6090366
Process for the preparation of an organ-specific substace labeled with technetium-99m
expired
Frequently asked questions
What is chlorotrianisene?
chlorotrianisene (TACE) is a estrogen receptor beta modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for chlorotrianisene?
TACE is a marketed brand name for chlorotrianisene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of chlorotrianisene?
chlorotrianisene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.